Acknowledgments
None.
Authors’ contributions
Yuan Hong and Xichuang Chen: Conceptualization, methodology, data curation, formal analysis, writing–original draft, and writing–review and editing, and funding acquisition. Xiaohong You: Investigation, data curation, software, validation, writing–original draft, and writing–review and editing. Yan Wang: Project administration, supervision, and data curation, and writing–original draft. Jingyi Mi: Project administration, supervision, data curation, and writing–review and editing; Xingfang Xiao and Yuanquan Hong: Investigation, data curation, software, validation, and writing-review and editing. Tao Zhou: Data curation, software, validation, formal analysis. Panpan Zheng: Data curation, formal analysis, writing–original draft, and writing-review and editing. Zhihu Huang: Conceptualization, investigation, and data curation. All authors read and approved the final manuscript.
Funding
The study was supported by grants from Wuxi Taihu Lake Talent Plan High Level Talent Training Project (HB2020115/BJ2020087), and Scientific Research Project of Jiangsu Pharmaceutical Society (A202018). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the article.
Availability of data and materials
The datasets generated or analyzed during the current study are from the following published articles: (1) Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517-2528, doi:10.1056/NEJMoa1812836., (2) Fink AM, Bahlo J, Robrecht S, et al. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017;4(10):e475-e486, doi:10.1016/S2352-3026(17)30171-0., (3) Cull G, Burger JA, Opat S, et al. Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AU-003 study. Br J Haematol. 2022;196(5):1209-1218, doi:10.1111/bjh.17994., (4) Xu W, Song Y, Wang T, et al. Updated results from the phase II study of orelabrutinib monotherapy in Chinese patients with relapsed or refractory chronic lymphocytic leukemia/ small cell leukemia [abstract]. Blood. 2020;136(Suppl. 1):26-27, https://doi.org/10.1182/blood-2020-134531, (5) Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223, doi:10.1056/NEJMoa1400376., (6) Munir T, Brown JR, O’Brien S, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94(12):1353-1363, doi:10.1002/ajh.25638., and (7) Else M, Wade R, Oscier D, et al. The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years. Br J Haematol. 2016;172(2):228-237, doi:10.1111/bjh.13824.
Ethics approval and consent participate
This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors, it does not require the approval of the independent ethics committee.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.